Navigating the Evolving Treatment Landscape in HER2-mutated NSCLC

A panel of thoracic oncologists have a comprehensive discussion on the treatment of HER2 non–small cell lung cancer, covering diagnosis, therapies, clinical trials, and unmet needs in the treatment space.

EP. 1: Diagnosing HER2-mutated NSCLC

April 17th 2024

A panel of thoracic oncologists introduce themselves and discuss biomarker testing strategies and the diagnosis of HER2 non–small cell lung cancer (NSCLC).

EP. 2: Biomarker Testing Challenges in HER2-mutated NSCLC

April 17th 2024

Experts on HER2 non–small cell lung cancer provide clinical insights on biomarker testing challenges and the role of reflex testing.

EP. 3: Role of ADCs in HER2-Mutated NSCLC

April 24th 2024

The panel discusses the role of antibody-drug conjugates (ADCs) and the treatment of patients with HER2 non–small cell lung cancer.

EP. 4: DESTINY-Lung01 & DESTINY-Lung02: T-DXd in Metastatic HER2-Mutated NSCLC

April 24th 2024

Lyudmila A. Bazhenova, MD, and D. Ross Camidge, MD, PhD, review the DESTINY-Lung01 and DESTINY-Lung02 trials, and the panel provides its impressions of the data.

EP. 5: The Role of Trastuzumab Deruxtecan in HER2-Mutated NSCLC

May 1st 2024

Experts on HER2 NSCLC discuss the patient populations in which they’d utilize trastuzumab deruxtecan and share their clinical experiences with the therapy.

EP. 6: DESTINY-Lung04: First-Line Trastuzumab Deruxtecan in HER2-Mutated NSCLC

May 1st 2024

Edward S. Kim, MD, MBA, discusses the DESTINY-Lung04 trial, a study evaluating trastuzumab deruxtecan as first-line treatment for patients with HER2 NSCLC.